Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication

Abdelsalam, Ramy A.; Khalifeh, Ibrahim; Box, Adrian; Kalantarian, Maria; Ghosh, Sunita; Abou-Ouf, Hatem; Lotfi, Tamara; Shahait, Mohammed; Palanisamy, Nallasivam; Bismar, Tarek A.

doi:10.1007/s00432-020-03221-x

Cited by 7 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased prevalence was observed in western countries (54%) as compared to Asian countries (23%) 2 . Study conducted by Abdelsalam et al, demonstrated 42.7% ERG positive prostate tumor in their cohort 15 . Forty nine percent incidence was documented by verdu et al 16 .…”

Section: Prostatic Adenocarcinoma Is Second Most Common Malignancy Worldwide Particularly In Europeanmentioning

confidence: 78%

Expression of Erg Immunohistochemical Stain in Prostatic Adenocarcinoma

Tabish

Khan

Mushtaq

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: The objective of my study is to investigate the incidence ERG fusion positive adenocarcinoma and its correlation with gleason grade and gleason group. Methods: it is a descriptive cross sectional study. 100 cases of prostatic adenocarcinoma were retrieved and ERG immunohistochemical stain was applied on all these cases. ERG expression, extent of staining, percentage of tumor cells positive for ERG, pattern of staining were recorded. We found out relationship of ERG expression and gleason grade/ gleason group. Results: ERG expression was seen in 62/100 (62%) cases. mean patient age of ERG positive prostatic adenocarcinoma patients was 69.68years. In GG1 (14.5%) 9 cases exhibited ERG positivity. In GG2-3, 41.93% cases and in GG4-5, 43.54% cases showed ERG expression. Conclusion: To conclude, age of presentation of ERG positive adenocarcinoma was high. ERG expression was seen in 62% of our cases which was much higher than reported in other Asian countries. In our study we found a significant correlation between ERG expression and high gleason grade group.

show abstract

Section: Prostatic Adenocarcinoma Is Second Most Common Malignancy Worldwide Particularly In Europeanmentioning

confidence: 78%

Expression of Erg Immunohistochemical Stain in Prostatic Adenocarcinoma

Tabish

Khan

Mushtaq

et al. 2021

PAFMJ

View full text Add to dashboard Cite

show abstract

“…Most of our patients achieved good response of ADT, so changing the therapy protocol or adding a new agent were not necessary. These findings do emphasis on the variations in progression and prognostication of PCa; therefore, validation of western therapeutic protocols for the managements of PCa is recommend for other nations and societies [4].…”

Section: Discussionmentioning

confidence: 97%

“…In the USA alone, there will be an estimated 191,000 cases of PCa diagnosed in the year 2020 of which approximately 20% will be metastatic [3]. In the Middle Eastern population, there are variations in PCa incidence, progression, and prognostication compared to the Western population which may be due to significant difference in key molecular events [4]. African-American men have a higher risk of lethal PCa compared to European-American men [5].…”

Section: Introductionmentioning

confidence: 99%

Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy

et al. 2021

View full text Add to dashboard Cite

Purpose To define the efficacy of standard androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer (PCa). Materials and methods Fifty patients with mean age of 70.48 ± 9.95 years old (range 52–87) who had metastatic PCa and received ADT between 2014 and 2019 were retrospectively evaluated. Median values of pre-therapeutic PSA and Gleason scores were 50 ng/ml (range 8–1201) and 8 (range 6–9), respectively. All patients received luteinizing hormone-releasing hormone (LHRH) analogue and anti-androgen. The patients were evaluated in terms of age, pre-therapeutic PSA serum levels, Gleason scores, presence of metastasis, number and percentage of cores involved, nadir PSA, time to nadir PSA, duration of ADT, and PSA at last follow-up. Multivariate analysis was used to define the factors which have impact on ADT response. The mean follow-up period was 13.87 ± 7.78 months, (range 2–32). Results All patients showed reduction in serum PSA level after initiation of ADT, and the median value of nadir PSA was 1.12 ng/ml (range 0.02–50). The mean value of time to nadir PSA was 3.85 ± 1.57 months (range 2–7). The median value of PSA at last follow-up was 2 ng/ml (range 0.02–50.21). Multi-variant analysis showed that nadir PSA have a significant correlation with pre-therapeutic PSA, PSA at last follow-up, age, and Gleason scores (p < .05). Conclusion Standard ADT is a feasible option in the treatment of metastatic PCa. Gleason scores, age, pre-therapeutic PSA, and PSA at last follow-up have significant impact on outcomes of ADT. Further studies of high number of patients with long-term follow-up including other chemo-hormonal therapy and androgen receptor blockers should be carried out to confirm and improve efficacy of ADT.

show abstract

“…In previous work, we investigated the significance and incidence of key genetic alterations related to ERG , PTEN, and SPINK1 in a different Middle Eastern cohort relative to a different European cohort [ 9 ]. The study documented that ERG , PTEN, and SPINK1 genomic alterations occurred less frequently in the Middle Eastern cohort and that an enrichment of ERG and PTEN loss was not observed.…”

Section: Discussionmentioning

confidence: 99%

“…In a similar way, several somatic genomic alterations differ in frequency between ancestries, including TMPRSS2-ERG genomic rearrangements, SPINK1 overexpression, and SPOP single nucleotide variants (SNVs), supporting differences in prostate cancer risk and pathway progression [ 7 , 8 ]. The rate of PTEN loss, as assessed by IHC, is lower in men of ME ethnicity, and tumors with PTEN loss are not enriched for ERG loss, as documented in EUR cohorts [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry

Albawardi

Livingstone

Almarzooqi

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Our knowledge of prostate cancer (PCa) genomics mainly reflects European (EUR) and Asian (ASN) populations. Our understanding of the influence of Middle Eastern (ME) and African (AFR) ancestry on the mutational profiles of prostate cancer is limited. To characterize genomic differences between ME, EUR, ASN, and AFR ancestry, fluorescent in situ hybridization (FISH) studies for NKX3-1 deletion and MYC amplification were carried out on 42 tumors arising in individuals of ME ancestry. These were supplemented by analysis of genome-wide copy number profiles of 401 tumors of all ancestries. FISH results of NKX3-1 and MYC were assessed in the ME cohort and compared to other ancestries. Gene level copy number aberrations (CNAs) for each sample were statistically compared between ancestry groups. NKX3-1 deletions by FISH were observed in 17/42 (17.5%) prostate tumors arising in men of ME ancestry, while MYC amplifications were only observed in 1/42 (2.3%). Using CNAs called from arrays, the incidence of NKX3-1 deletions was significantly lower in ME vs. other ancestries (20% vs. 52%; p = 2.3 × 10−3). Across the genome, tumors arising in men of ME ancestry had fewer CNAs than those in men of other ancestries (p = 0.014). Additionally, the somatic amplification of 21 specific genes was more frequent in tumors arising in men of ME vs. EUR ancestry (two-sided proportion test; Q < 0.05). Those included amplifications in the glutathione S-transferase family on chromosome 1 (GSTM1, GSTM2, GSTM5) and the IQ motif-containing family on chromosome 3 (IQCF1, IQCF2, IQCF13, IQCF4, IQCF5, IQCF6). Larger studies investigating ME populations are warranted to confirm these observations.

show abstract

Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication

Cited by 7 publications

References 51 publications

Expression of Erg Immunohistochemical Stain in Prostatic Adenocarcinoma

Expression of Erg Immunohistochemical Stain in Prostatic Adenocarcinoma

Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy

Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry

Contact Info

Product

Resources

About